| Literature DB >> 26958489 |
Niki Karachaliou1, Sara Pilotto1, Chiara Lazzari1, Emilio Bria1, Filippo de Marinis1, Rafael Rosell1.
Abstract
Although the incidence of small cell lung cancer (SCLC) has declined during the past 30 years, it remains a frustrating disease to research and treat. Numerous attempts to enhance the anti-tumor effects of traditional chemotherapy for SCLC have not been successful. For any tumor to become cancerous, various genetic mutations and biologic alterations must occur in the cell that, when combined, render it a malignant neoplasm. New and novel therapies based on understanding these mechanisms of transformation are needed. Herein we provide an in-depth view of some of the genomic alterations in SCLC that have emerged as potential targets for therapeutic intervention.Entities:
Keywords: Small cell lung cancer (SCLC); biomarkers; immune system; targeted therapies
Year: 2016 PMID: 26958489 PMCID: PMC4758976 DOI: 10.3978/j.issn.2218-6751.2016.01.02
Source DB: PubMed Journal: Transl Lung Cancer Res ISSN: 2218-6751